Oncotrace RGCC
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.
During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration and specific type (immunophenotype).
The results of the test enable clinicians to identify the origin of a tumour where this is unknown and to provide information on the development of cancer and the prognosis.
Purpose of the test
Purpose of the test
Oncotrace RGCC is a highly-effective way of diagnosing cancer and identifying the location of a primary tumour, and its current stage of development.
Scientists analyse a blood sample to identify whether CTCs exist and in what concentration. By identifying specific CTCs, scientists can diagnose where a tumour is and a patient’s prognosis.
Evidence has shown that flow-cytometry testing is highly accurate, and the method has been assessed for sensitivity.
One cancer has been confirmed, additional tests offered by RGCC can be used to identify the most effective treatments.
Useful information
Useful information
Circulating tumour cells (CTCs) are cells that have detached from the primary tumour and entered the bloodstream. Using a technique called flow cytometry, scientists can search for these cells (or biomarkers) in a blood sample.
Oncotrace RGCC is suitable for diagnosing all common forms of cancer.
The test requires 7 to 10 ml of whole (peripheral) blood. Once returned to the laboratory, scientists will analyse the sample to identify the prevalence of specific CTCs. The results will be interpreted by a clinician who will be able to identify the locations, spread and severity of your primary tumour and treatment prognosis.
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on how to access, perform or analyse the results of the Oncotrace RGCC test, then get in touch today.